Marty Makary

FDA

Fierce Pharma

Under Trump, FDA seeks to abandon expert reviews of new drugs

FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications.

Arthur Allen, KFF Health News Sep 12, 2025 9:50am

Image of a neon sign with the word no lit up next to an unlit yes

FDA rejects another ultrarare disease prospect

Sep 8, 2025 10:59am

FDA

FDA plans real-time release of drug rejection letters

Sep 4, 2025 1:45pm

yellow road to bright light

FDA proposes new approval pathway for rare diseases

Sep 3, 2025 1:20pm

dominoes fall series fail

Krystal discontinues melanoma study after FDA's Replimune rebuff

Aug 21, 2025 10:50am

clock delay wait time alarm

Regenxbio's Hunter gene therapy latest to face FDA delay

Aug 19, 2025 10:30am